Literature DB >> 15691245

Overview of observational studies of low-dose helical computed tomography screening for lung cancer.

Renee L Manser1, Louis B Irving, Margaret P de Campo, Michael J Abramson, Christine A Stone, Karen E Pedersen, Mark Elwood, Donald A Campbell.   

Abstract

OBJECTIVE: Lung cancer is a substantial public health problem in Western countries. Evidence from previous controlled trials of chest radiography and sputum cytology does not support lung cancer screening, but computed tomography (CT) screening has recently emerged as a more sensitive screening tool. For the present article, the available observational studies of low-dose helical CT screening for lung cancer were reviewed.
METHODOLOGY: An evidence-based review of all published observational studies of low-dose helical CT screening for lung cancer, identified by an extensive search of Medline, was conducted.
RESULTS: Eight observational studies of CT screening for lung cancer were identified. Relative to chest radiography, low-dose helical CT is a sensitive screening tool and can detect a high proportion of small lung cancers at an early and resectable stage. The yield of sputum cytology in addition to CT screening appears to be relatively low. To date, 5-year lung cancer survival of all individuals participating in baseline screening has not been reported for any of the studies.
CONCLUSIONS: Although these preliminary studies are very promising, it remains to be proven that the early detection and treatment of lung cancer will lead to a reduction in mortality. This issue will be addressed by randomized controlled trials. In the interim, the long-term follow up of these observational studies could provide further insights.

Entities:  

Mesh:

Year:  2005        PMID: 15691245     DOI: 10.1111/j.1440-1843.2005.00590.x

Source DB:  PubMed          Journal:  Respirology        ISSN: 1323-7799            Impact factor:   6.424


  6 in total

1.  Lung cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.

Authors:  William G Hocking; Ping Hu; Martin M Oken; Stephen D Winslow; Paul A Kvale; Philip C Prorok; Lawrence R Ragard; John Commins; David A Lynch; Gerald L Andriole; Saundra S Buys; Mona N Fouad; Carl R Fuhrman; Claudine Isaacs; Lance A Yokochi; Thomas L Riley; Paul F Pinsky; John K Gohagan; Christine D Berg
Journal:  J Natl Cancer Inst       Date:  2010-05-04       Impact factor: 13.506

2.  Diagnostic work-up and surgery in participants of the Gdansk lung cancer screening programme: the incidence of surgery for non-malignant conditions.

Authors:  Witold Rzyman; Malgorzata Jelitto-Gorska; Robert Dziedzic; Iwona Biadacz; Janina Ksiazek; Piotr Chwirot; Tomasz Marjanski
Journal:  Interact Cardiovasc Thorac Surg       Date:  2013-09-05

3.  Patient willingness and barriers to receiving a CT scan for lung cancer screening.

Authors:  Jennifer Delmerico; Andrew Hyland; Paula Celestino; Mary Reid; K Michael Cummings
Journal:  Lung Cancer       Date:  2014-03-13       Impact factor: 5.705

4.  Psf3 as a possible biomarker of postoperative chemotherapy for patients with early pulmonary adenocarcinoma.

Authors:  Kenji Kimura; Yugo Tanaka; Shunsuke Tauchi; Yoshitaka Kitamura; Wataru Nishio; Yasuhiro Sakai; Yoshitake Hayashi; Masahiro Yoshimura; Yoshimasa Maniwa
Journal:  Thorac Cancer       Date:  2019-10-22       Impact factor: 3.500

5.  Status and perspectives of detection by low-dose computed tomography or computed radiography in surgical patients with lung cancer, based on a five-year study.

Authors:  Yutian Lai; Cheng Shen; Xin Wang; Heng Du; Dali Chen; Long Tian; Xudong Zhou; Guowei Che
Journal:  Thorac Cancer       Date:  2015-07-24       Impact factor: 3.500

6.  [Classification and Risk-factor Analysis of Postoperative Cardio-pulmonary 
Complications after Lobectomy in Patients with Stage I Non-small Cell Lung Cancer].

Authors:  Yutian Lai; Jianhua Su; Mingming Wang; Kun Zhou; Heng Du; Jian Huang; Guowei Che
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2016-05-20
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.